OBJECTIVES: To assess the influence of different treatment schemes of post-stroke spasticity on societal costs in Russia. METHODS: Analytical model of decision-making in Microsoft Excel 2013 was designed for assessing an influence of local standard therapy and different types of botulinum toxin (abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA) on the societal costs. Societal costs included: disability pensions, temporary disability benefit and GDP loss of due to loss of working force in case post-stroke spasticity. Disability assessment scale score was used as efficacy criteria. The main domains of this scale (0 – normal life, 3 – full disability) were compared with Russian disability group system (1st group of disability – severe grade, 3d group – mild grade). According to the information retrieval using Ministry of trade and social development database and clinical trials data it was found that in 2014 out of 287,314 people with post-stroke spasticity  there were 12,7% disabled people of 1st grade, 32,7% of 2nd one and 34,6% of 3d one. 20% of people have no disability group. For reference, accepted exchange rate was 1 US$ = 60,29 RUB.   RESULTS: Therapy with abobotulinumtoxinA allows to decrease disability level with 16%-efficacy, therapy with onabotulinumtoxinA with 12,6 %-efficacy, standard therapy with 3,3%-efficacy. Consequently, societal costs economy for whole population of post-stroke spasticity patients for one year is US$ 378,97 million higher compared with standard therapy, US$ 119,21 million higher compared with onabotulinumtoxinA treatment scheme, and US$ 129,47 million higher compared with incobotulinumtoxinA treatment scheme. CONCLUSIONS: AbobotulinumtoxinA treatment scheme shows more prominent decrease of disability level in post-stroke spasticity patients in Russia and allows to decrease societal costs to a greater extent compared with other alternatives. That fact makes abobotulinumtoxinA more beneficial from the societal costs perspective compared with other treatment schemes.